The benefits of the potential therapy of Glucox Biotech are that it effectively increase glucose uptake in muscle and dramatically improves insulin sensitivity and thus remove the probable cause of the blunted insulin response. This is in a way the opposite effect of what drugs on the market do when stimulating insulin secretion from pancreatic cells.
Chronic hyperglycaemia is the main cause of increased oxidative stress in type 2 diabetes patients. The over-production of oxygen free radicals, ROS, and nitric oxide radicals leads to the damage of many cellular compounds including lipids, proteins and nucleic acids.
Glucox Biotech’s development compounds are designed to inhibit one of the main enzymes involved in ROS production, NAD(P)H-oxidase (isoenzyme NOX4), thus aiming to reduce ROS production in diabetic subjects. NAD(P)H-oxidase related ROS has repeatedly been identified by several independent scientists as a key component in insulin resistance and the development of diabetes complications.
Based on its scientific excellence, favourable IP-position and with a strong mission, Glucox Biotech aims to develop and produce the next generation safe and beneficial therapy for present and future diabetes suffers.